Colgate-Palmolive Company (CL)
NYSE: CL · Real-Time Price · USD
84.71
+0.10 (0.12%)
At close: Aug 7, 2025, 4:00 PM
84.04
-0.67 (-0.79%)
After-hours: Aug 7, 2025, 7:40 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Regulus Therapeutics stock have a consensus rating of "Buy" and an average price target of $98.67, which forecasts a 16.48% increase in the stock price over the next year. The lowest target is $83 and the highest is $109.
Price Target: $98.67 (+16.48%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 3 | 3 |
| Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Hold | 7 | 7 | 7 | 7 | 6 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 1 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 14 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $108 → $105 | Strong Buy | Maintains | $108 → $105 | +23.95% | Aug 4, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $99 → $95 | Buy | Maintains | $99 → $95 | +12.15% | Aug 4, 2025 |
| Morgan Stanley | Morgan Stanley | Buy Maintains $104 → $96 | Buy | Maintains | $104 → $96 | +13.33% | Aug 4, 2025 |
| Wells Fargo | Wells Fargo | Sell Maintains $88 → $83 | Sell | Maintains | $88 → $83 | -2.02% | Aug 4, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $103 → $99 | Buy | Maintains | $103 → $99 | +16.87% | Jul 25, 2025 |
Financial Forecast
Revenue This Year
20.93B
from 20.10B
Increased by 4.11%
Revenue Next Year
21.80B
from 20.93B
Increased by 4.15%
EPS This Year
3.78
from 3.51
Increased by 7.58%
EPS Next Year
4.05
from 3.78
Increased by 7.35%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 21.5B | 22.7B | 23.5B | ||
| Avg | 20.9B | 21.8B | 22.7B | ||
| Low | 19.7B | 20.3B | 21.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 6.9% | 8.4% | 7.9% | ||
| Avg | 4.1% | 4.2% | 4.0% | ||
| Low | -1.9% | -2.9% | -3.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.89 | 4.29 | 4.71 | ||
| Avg | 3.78 | 4.05 | 4.35 | ||
| Low | 3.56 | 3.77 | 4.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 10.7% | 13.7% | 16.3% | ||
| Avg | 7.6% | 7.3% | 7.4% | ||
| Low | 1.5% | -0.1% | -0.6% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.